Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 1.00 |
| ▸ | EBP | Q15125 | 2/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | EBPL | Q9BY08 | 1/20 | 0.86 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| [11C]Sa4503 SCHEMBL29358558 | 1.00 | SIGMAR1 (1.00) | SIGMAR1EBPTMEM97EBPLABCB1 | |
| [11C]Sa4503 SCHEMBL29358694 | 0.99 | SIGMAR1 (0.97) | SIGMAR1EBPTMEM97EBPLABCB1 | |
| [11C]Sa4503 SCHEMBL1299046 | 0.99 | SIGMAR1 (0.97) | SIGMAR1EBPTMEM97EBPLABCB1 | |
| Hydrochloric Acid SCHEMBL8088187 | 0.99 | SIGMAR1 (0.97) | SIGMAR1EBPTMEM97EBPLABCB1 | |
| SCHEMBL8083210 | 0.97 | SIGMAR1 (0.95) | SIGMAR1EBPTMEM97EBPLABCB1 | |
| SCHEMBL8086559 | 0.96 | SIGMAR1 (0.92) | SIGMAR1EBPTMEM97EBPLABCB1 | |
| Hydrochloric Acid SCHEMBL8075024 | 0.96 | SIGMAR1 (0.92) | SIGMAR1EBPTMEM97EBPLABCB1 | |
| Hydrochloric Acid SCHEMBL8086545 | 0.95 | SIGMAR1 (0.90) | SIGMAR1EBPTMEM97EBPLABCB1 | |
| SCHEMBL8075010 | 0.94 | SIGMAR1 (0.89) | SIGMAR1EBPTMEM97EBPL | |
| Hydrochloric Acid SCHEMBL8074974 | 0.94 | SIGMAR1 (0.88) | SIGMAR1EBPTMEM97EBPLABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116981449-A | Compounds and compositions for inducing neuroprotection | 瑞斯特医疗公司 | 2023-10-31 | — | — | CN | claimed |
| EP-4142703-B1 | COMPOUND AND COMPOSITION FOR INDUCING NEUROPROTECTION | REST THERAPEUTICS (FR) | 2023-10-18 | — | — | EP | claimed |
| US-20230270695-A1 | COMPOUND AND COMPOSITION FOR INDUCING NEUROPROTECTION | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2023-08-31 | — | — | US | claimed |
| EP-4142703-A1 | COMPOUND AND COMPOSITION FOR INDUCING NEUROPROTECTION | REST THERAPEUTICS (FR) | 2023-03-08 | — | — | EP | claimed |
| WO-2021234324-A1 | COMPOUND AND COMPOSITION FOR INDUCING NEUROPROTECTION | REST THERAPEUTICS (FR) | 2021-11-25 | — | — | WO | claimed |
| EP-3880209-A1 | COMPOSITIONS AND METHODS FOR REGULATING INFLAMMATION | University of Virginia Patent Foundation (US) | 2021-09-22 | — | — | EP | claimed |
| EP-3104847-B1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | MTA TAMOGATOTT KUTATOCSOPORTOK IRODAJA (HU) | 2020-11-11 | — | — | EP | claimed |
| WO-2020118086-A1 | COMPOSITIONS AND METHODS FOR REGULATING INFLAMMATION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-06-11 | — | — | WO | claimed |
| CN-106456578-B | Use of SIGMA-1 receptor agonist compounds | 匈牙利科学院大学及其他机构附属研究所 | 2020-02-18 | — | — | CN | claimed |
| CN-106456578-A | Novel use of SIGMA-1 receptor agonist compounds | 匈牙利科学院大学及其他机构附属研究所 | 2017-02-22 | — | — | CN | claimed |
| WO-2015118365-A1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | MTA TÁMOGATOTT KUTATÓCSOPORTOK IRODÁJA (HU) | 2015-08-13 | — | — | WO | claimed |
| US-20110152284-A1 | Sigma ligands for neuronal regeneration and functional recovery | WIELOCH TADEUSZ | 2011-06-23 | — | — | US | claimed |
| US-20110015209-A1 | Sigma ligands for neuronal regeneration and functional recovery | M'S SCIENCE CORPORATION | 2011-01-20 | — | — | US | claimed |
| US-7863272-B2 | Sigma ligands for neuronal regeneration and functional recovery | M'S SCIENCE CORPORATION (JP) | 2011-01-04 | — | — | US | claimed |
| US-7829562-B2 | Sigma ligands for neuronal regeneration and functional recovery | M'S SCIENCE CORPORATION (JP) | 2010-11-09 | — | — | US | claimed |
| WO-2008060271-A1 | SIGMA LIGANDS FOR NEURONAL REGENERATION AND FUNCTIONAL RECOVERY | M'S SCIENCE CORPORATION (JP) | 2008-05-22 | — | — | WO | claimed |
| US-6436938-B1 | ADMINISTERING A SIGMA RECEPTOR LIGAND IN COMBINATION WITH AN ANTIDEPRESSANT AGENT; ESPECIALLY FOR REFRACTORY DEPRESSION | PFIZER INC. | 2002-08-20 | — | — | US | claimed |
| US-20020099045-A1 | Combination treatment for depression | PFIZER PRODUCTS INC. | 2002-07-25 | — | — | US | claimed |
| EP-1224930-A1 | Combination of a SR inhibitor and sigma receptor ligand in the treatment ofdepression | Pfizer Products Inc. (US) | 2002-07-24 | — | — | EP | claimed |
| WO-2002030422-A1 | USE OF DEFINED SUBSTANCES THAT BIND TO THE SIGMA RECEPTOR FOR COMBATING SARCOMA AND CARCINOMA | MERCK PATENT GMBH (DE) | 2002-04-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152284-A1 | Sigma ligands for neuronal regeneration and functional recovery | SIGMAR1, TMEM97, LPAR6 | SIGMAR1 1/4885EBP 894/4885TMEM97 2/4885 |
| US-20230270695-A1 | COMPOUND AND COMPOSITION FOR INDUCING NEUROPROTECTION | BDNF, GAP43, NLN | SIGMAR1 1214/4885EBP 68/4885TMEM97 1922/4885 |
| US-20110015209-A1 | Sigma ligands for neuronal regeneration and functional recovery | SIGMAR1, TMEM97, GPR6 | SIGMAR1 1/4885EBP 979/4885TMEM97 2/4885 |
| US-20020099045-A1 | Combination treatment for depression | HTR5A, HTR1A, OPRL1 | SIGMAR1 13/4885EBP 1526/4885TMEM97 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.